Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics.
Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics.
复制标题
DOI：
10.1615/critrevoncog.2014011455
复制
发表时间：
2014
影响因子：
--
通讯作者：
Bergkvist M
中科院分区：
文献类型：
--
作者：
Engelberth SA;Hempel N;Bergkvist M
卵巢癌是所有妇科癌症中最致命的，也是女性癌症导致的第五大死亡原因。这在很大程度上是由于晚期诊断，与晚期疾病相关的预后较差，以及与化疗耐药相关的高复发率。在过去30年中，存活率统计数据没有显著改善，这突显了这样一个事实，即改进的治疗策略和早期发现需要实质性的改善。在这里，我们回顾和强调基于纳米技术的方法，寻求解决这一需求。Doxil是一种聚乙二醇化的阿霉素脂质体纳米胶囊，被FDA批准用于治疗复发性卵巢癌，它的成功为当前药物发现和临床试验中的纳米颗粒制剂浪潮铺平了道路。我们讨论和总结目前正在进入临床试验的新的纳米配方，并强调在临床前体内研究中显示出有希望的结果的新的纳米治疗策略。此外，还讨论了纳米材料在诊断成像技术中的潜力以及利用纳米技术早期检测卵巢癌的能力。
Ovarian cancer is the deadliest of all gynecological cancers and the fifth leading cause of death due to cancer in women. This is largely due to late-stage diagnosis, poor prognosis related to advanced-stage disease, and the high recurrence rate associated with development of chemoresistance. Survival statistics have not improved significantly over the last three decades, highlighting the fact that improved therapeutic strategies and early detection require substantial improvements. Here, we review and highlight nanotechnology-based approaches that seek to address this need. The success of Doxil, a PEGylated liposomal nanoencapsulation of doxorubicin, which was approved by the FDA for use on recurrent ovarian cancer, has paved the way for the current wave of nanoparticle formulations in drug discovery and clinical trials. We discuss and summarize new nanoformulations that are currently moving into clinical trials and highlight novel nanotherapeutic strategies that have shown promising results in preclinical in vivo studies. Further, the potential for nanomaterials in diagnostic imaging techniques and the ability to leverage nanotechnology for early detection of ovarian cancer are also discussed.